Ciliate Host Cell Viral Protein Expression System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing viral vaccines, such as those using fertilized chicken eggs or mammalian cell cultures, are inefficient, costly, and lack flexibility in responding to rapidly changing viral strains, with issues like high egg procurement, long production times, and safety concerns due to complex media handling and potential adventitious virus contamination.
Innovation Solution
A system for heterologous expression of viral surface proteins using ciliate host cells, specifically Tetrahymena thermophila, which offers a safe, efficient, and flexible platform for producing viral proteins with optimized codon usage and post-translational modifications, including glycosylation patterns that enhance immunogenicity, by utilizing specific promoters and signal sequences to facilitate protein secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If fertilized chicken eggs are used for vaccine production, then production costs are reduced, but production time increases and flexibility decreases
Solution Approach 1:
The patent extracts the viral protein production function from the complex egg-based system and transfers it to a simplified cell culture system. By using mammalian cell lines that can be rapidly expanded in bioreactors, the invention separates the essential vaccination function from the cumbersome egg procurement and handling processes, achieving both cost-effectiveness and rapid production response.
Solution Approach 2:
The invention changes the fundamental production parameter from egg-based to cell-culture-based systems. This parameter change enables rapid scaling of production capacity by adjusting bioreactor volumes and cell culture conditions, while maintaining cost-effectiveness through standardized industrial fermentation processes.
2Adaptability or versatility
If mammalian cell cultures are used for vaccine production, then production flexibility and scalability are improved, but operational complexity and costs increase
Solution Approach 1:
The patent employs universal mammalian cell lines (such as HEK 293 or PER.C6) that can produce multiple different viral proteins through recombinant DNA technology. This universal platform can be rapidly reconfigured to produce vaccines against different viral strains by simply changing the inserted gene, thereby achieving high adaptability without increasing operational complexity.
Solution Approach 2:
The invention uses recombinant DNA technology to create copies of viral protein genes and insert them into the mammalian cell genome. This allows the cells to naturally produce the viral proteins through their own cellular machinery, eliminating the need for complex virus cultivation and purification procedures while maintaining protein authenticity and immunogenicity.
3Productivity
If viral proteins are expressed in prokaryotes like Escherichia coli, then production efficiency is improved, but post-translational modifications are lost
Solution Approach 1:
The patent introduces mammalian cells as an intermediary expression system that bridges the gap between prokaryotic production efficiency and eukaryotic protein modification capability. Mammalian cells naturally perform all necessary post-translational modifications (glycosylation, disulfide bond formation, folding) while being amenable to high-density culture and rapid scaling, thus achieving both efficiency and precision.
Solution Approach 2:
The invention creates a composite expression system that combines the advantages of both prokaryotic and eukaryotic systems. By using mammalian cell lines that can be cultured at high densities with controlled metabolism (prokaryotic-like efficiency) while maintaining eukaryotic protein modification machinery, the system achieves optimal balance between production speed and protein quality.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to a system for the heterologous expression of a viral protein or a fragment thereof, said system comprising a) a ciliate host cell, b) at least one cDNA encoding for a viral protein, or a fragment thereof, and c) a promoter operably linked to said cDNA.